Background Coronavirus disease 2019 (COVID-19) is associated with diffuse lung damage.
Corticosteroids may modulate immune-mediated lung injury and reducing progression to …

Background Lopinavir–ritonavir has been proposed as a treatment for COVID-19 on the basis
of in vitro activity, preclinical studies, and observational studies. Here, we report the results …

Background Large trials have shown that sodium glucose co-transporter-2 (SGLT2) inhibitors
reduce the risk of adverse kidney and cardiovascular outcomes in patients with heart …

Background REGEN-COV is a combination of 2 monoclonal antibodies (casirivimab and
imdevimab) that bind to two different sites on the receptor binding domain of the SARS-CoV-2 …

Background Treatment of COVID-19 patients with plasma containing anti-SARS-CoV-2
antibodies may have a beneficial effect on clinical outcomes. We aimed to evaluate the safety …

Diabetes is a common cause of chronic kidney disease (CKD), but in aggregate, non-diabetic
diseases account for a higher proportion of cases of CKD than diabetes in many parts of …

Background Ambulatory blood pressure provides a more comprehensive assessment than
clinic blood pressure, and has been reported to better predict health outcomes than clinic or …

Background: Coronavirus disease 2019 (Covid-19) is associated with diffuse lung damage.
Glucocorticoids may modulate inflammation-mediated lung injury and thereby reduce …

Background: Sacubitril/valsartan reduces the risk of cardiovascular mortality among patients
with heart failure with reduced ejection fraction, but its effects on kidney function and cardiac …

It is unclear whether a social gradient in health outcomes exists for people with moderate-to-severe
chronic kidney disease (CKD). We critically review the literature for evidence of …